Synthesis and biological evaluation of DIDS analogues as efficient inhibitors of RAD51 involved in homologous recombination
Related Experiment Video
Updated: Aug 5, 2025

Real-time Observation of the DNA Strand Exchange Reaction Mediated by Rad51
Published on: February 13, 2019
Alexandre Demeyer1, Lucie Fonteneau1, Marion Liennard2
1Nantes Université, CNRS, US2B, UMR 6286, DNA-repair Group, F-44000 Nantes, France.
Abstract:
RAD51 is a pivotal protein of the homologous recombination DNA repair pathway, and is overexpressed in some cancer cells, disrupting then the efficiency of cancer-treatments. The development of RAD51 inhibitors appears as a promising solution to restore these cancer cells sensitization to radio- or chemotherapy. From a small molecule identified as a modulator of RAD51, the 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS), two series of analogues with small or bulky substituents on the aromatic parts of the stilbene moiety were prepared for a structure-activity relationship study. Three compounds, the cyano analogue (12), and benzamide (23) or phenylcarbamate (29) analogues of DIDS were characterized as novel potent RAD51 inhibitors with HR inhibition in the micromolar range.
Insights
Researchers developed novel RAD51 inhibitors based on the DIDS molecule. These compounds show potential for enhancing cancer treatment efficacy by targeting homologous recombination DNA repair in cancer cells.
Area of Science:
- Biochemistry
- Molecular Biology
- Medicinal Chemistry
Background:
- RAD51 protein is crucial for homologous recombination DNA repair.
- Overexpression of RAD51 in cancer cells can reduce sensitivity to chemotherapy and radiotherapy.
- Targeting RAD51 offers a strategy to re-sensitize cancer cells to existing treatments.
Purpose of the Study:
- To develop novel RAD51 inhibitors.
- To investigate structure-activity relationships of DIDS analogues as RAD51 inhibitors.
- To identify potent RAD51 inhibitors for potential cancer therapy.
Main Methods:
- Synthesis of two series of 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS) analogues with varying substituents.
- Structure-activity relationship (SAR) studies.
- Assay of RAD51 inhibitory activity and homologous recombination (HR) inhibition.
Main Results:
- Several DIDS analogues were synthesized and evaluated for RAD51 inhibitory potential.
- Three compounds, including cyano (12), benzamide (23), and phenylcarbamate (29) analogues, demonstrated potent RAD51 inhibition.
- These novel inhibitors exhibited homologous recombination inhibition in the micromolar range.
Conclusions:
- The synthesized DIDS analogues represent a new class of potent RAD51 inhibitors.
- These compounds hold promise for restoring cancer cell sensitivity to radio- and chemotherapy.
- Further development of these inhibitors could lead to improved cancer treatment strategies.
Related Concept Videos
Homologous Recombination
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...
Diels–Alder Reaction: Characteristics of Dienes
Characteristics of the diene
Conformation
The simplest example of a diene is 1,3-butadiene, an acyclic conjugated π system. At room temperature, the molecule exists as a mixture of s-cis and s-trans conformers by virtue of rotation around the carbon–carbon single bond. Although the s-trans isomer is...

